January 25, 2019 07:30 AM EST

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

Amber Tong

A week after Eli Lilly reported the confirmatory study for its cancer drug Lartruvo had failed to help patients live longer, the FDA is discouraging …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

In an­oth­er set­back for Eli Lil­ly, FDA fol­lows EMA in call­ing for a halt to new Lartru­vo pre­scrip­tions

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?